iHealthScreen (iHS) Inc. has developed iPredict™, an AI- and cloud-based platform for automated screening, prediction, and referral of patients at risk for major ocular and systemic diseases. iHS has received FDA clearance for its autonomous diabetic retinopathy (DR) screening product, along with CE certification and regulatory approvals in the UK, Australia, and Abu Dhabi for AMD, DR, and glaucoma screening. FDA clearance for AMD is expected by early-to-mid 2027. The iPredict™ pipeline also includes hypertensive retinopathy (HTNR), cardiovascular disease (CVD), and stroke. Current customers and deployments include U.S. clinics, Burjeel Hospital in the UAE, Endocrinology Melbourne in Australia, and the Bangladesh Diabetes Society, with 5.5 million registered patients with diabetes.